See more : Tharisa plc (THS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Peak Bio, Inc. (PKBOW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Peak Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- BioNexus Gene Lab Corp. (BGLC) Income Statement Analysis – Financial Results
- Western Metals Corporation (WTLC) Income Statement Analysis – Financial Results
- Polytronics Technology Corp. (6224.TW) Income Statement Analysis – Financial Results
- Pakka Limited (PAKKA.NS) Income Statement Analysis – Financial Results
- TCL Zhonghuan Renewable Energy Technology Co.,Ltd. (002129.SZ) Income Statement Analysis – Financial Results
Peak Bio, Inc. (PKBOW)
About Peak Bio, Inc.
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 367.88K | 607.68K | 528.31K | 0.00 | 0.00 |
| Cost of Revenue | 107.10 | 108.58 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 367.77K | 607.57K | 528.31K | 0.00 | 0.00 |
| Gross Profit Ratio | 99.97% | 99.98% | 100.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 3.92M | 7.12M | 0.00 | 0.00 |
| General & Administrative | 218.68 | 8.53M | 2.47M | 332.09 | 173.88 |
| Selling & Marketing | 9.06 | 8.86 | 18.19 | 99.02 | 16.94 |
| SG&A | 1.25K | 8.53M | 2.47M | 2.35K | 1.23K |
| Other Expenses | 0.00 | -819.06K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.25K | 12.46M | 9.59M | 2.61K | 1.27K |
| Cost & Expenses | 1.36K | 12.46M | 9.59M | 2.61K | 1.27K |
| Interest Income | 202.80 | 2.11K | 160.00 | 149.30 | 1.56 |
| Interest Expense | 0.00 | 47.96K | 11.47K | 0.00 | 0.00 |
| Depreciation & Amortization | 54.73 | 786.48K | 176.65K | 39.27 | 8.37 |
| EBITDA | -1.36K | -12.33M | -8.02M | -2.35K | -1.23K |
| EBITDA Ratio | -0.37% | -1,954.70% | -1,682.49% | 0.00% | 0.00% |
| Operating Income | -1.36K | -11.85M | -9.07M | -2.39K | -1.24K |
| Operating Income Ratio | -0.37% | -1,949.68% | -1,715.95% | 0.00% | 0.00% |
| Total Other Income/Expenses | 96.97 | -44.14 | 855.02K | -107.97 | -37.41 |
| Income Before Tax | -1.26K | -13.16M | -8.21M | -2.46K | -1.27K |
| Income Before Tax Ratio | -0.34% | -2,166.06% | -1,554.11% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -74.00K | 82.07K | 0.00 | 0.00 |
| Net Income | -1.26K | -13.09M | -8.29M | -2.46K | -1.27K |
| Net Income Ratio | -0.34% | -2,153.88% | -1,569.65% | 0.00% | 0.00% |
| EPS | 0.00 | -0.74 | -0.48 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.74 | -0.48 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 29.54M | 17.71M | 17.16M | 6.72M | 3.64M |
| Weighted Avg Shares Out (Dil) | 29.54M | 17.71M | 17.16M | 6.72M | 3.64M |
Source: https://incomestatements.info
Category: Stock Reports